CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS

3.4.1. MARKET DYNAMICS
3.4.2. Drivers
3.4.3. Restraints
3.4.4. Opportunities

CHAPTER 4 MORPHINE MARKET, BY TYPE 

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. ORAL TABLETS

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. INJECTION 

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.4. CAPSULE 

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

4.5. OTHERS 

4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast

CHAPTER 5 MORPHINE MARKET, BY APPLICATION

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. ANESTHESIA 

5.2.1. Market size and forecast

5.3. COUGH SUPPRESSANT

5.3.1. Market size and forecast

5.4. DIARRHEA SUPPRESSANT

5.4.1. Market size and forecast

CHAPTER 6 MORPHINE MARKET, BY GEOGRAPHY

6.1. OVERVIEW
6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast

6.2.3.1. U.S. market size and forecast
6.2.3.2. Canada market size and forecast
6.2.3.3. Mexico market size and forecast

6.2.4. North America Morphine Market by Type
6.2.5. North America Morphine Market by Application

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast

6.3.3.1. Germany market size and forecast
6.3.3.2. France market size and forecast
6.3.3.3. UK market size and forecast
6.3.3.4. Italy market size and forecast
6.3.3.5. Spain market size and forecast
6.3.3.6. The Netherlands market size and forecast
6.3.3.7. Norway market size and forecast
6.3.3.8. Russia market size and forecast
6.3.3.9. Sweden market size and forecast
6.3.3.10. Switzerland market size and forecast
6.3.3.11. Rest of Europe market size and forecast

6.3.4. Europe Morphine Market by Type
6.3.5. Europe Morphine Market by Application

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast

6.4.3.1. Japan market size and forecast
6.4.3.2. China market size and forecast
6.4.3.3. Australia market size and forecast
6.4.3.4. India market size and forecast
6.4.3.5. South Korea market size and forecast
6.4.3.6. Taiwan market size and forecast
6.4.3.7. New Zealand market size and forecast
6.4.3.8. Thailand market size and forecast
6.4.3.9. Rest of Asia-Pacific market size and forecast

6.4.4. Asia-Pacific Morphine Market by Type
6.4.5. Asia-Pacific Morphine Market by Application

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast

6.5.3.1. Brazil market size and forecast
6.5.3.2. Chile market size and forecast
6.5.3.3. Saudi Arabia market size and forecast
6.5.3.4. South Africa market size and forecast
6.5.3.5. Columbia market size and forecast
6.5.3.6. Egypt market size and forecast
6.5.3.7. Iran market size and forecast
6.5.3.8. Israel market size and forecast
6.5.3.9. Venezuela market size and forecast
6.5.3.10. Turkey market size and forecast
6.5.3.11. Rest of LAMEA market size and forecast

6.5.4. LAMEA Morphine Market by Type 
6.5.5. LAMEA Morphine Market by Application

CHAPTER 7 COMPANY PROFILES

7.1. MALLINCKRODT PHARMACEUTICALS

7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments

7.2. ALCALIBER SA

7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments

7.3. PURDUE PHARMA L.P

7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments

7.4. SANOFI WINTHROP INDUSTRIE

7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments

7.5. MACFARLAN SMITH

7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments

7.6. SUN PHARMACEUTICAL INDUSTRIES LTD.

7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments

7.7. QINGHAI PHARMACEUTICAL CO. LTD.

7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments

7.8. NORTHEAST PHARMACEUTICAL GROUP CO., LTD

7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments